a Center for Business Studies , Institute of Education and Research (Insper) , Sao Paulo , Brazil.
Glob Public Health. 2018 Apr;13(4):489-502. doi: 10.1080/17441692.2017.1396354. Epub 2017 Nov 3.
The global health community is increasingly advocating for the local production of pharmaceuticals in developing countries as a way to promote technology transfer, capacity building and improve access to medicines. However, efforts to advance drug manufacturing in these countries revive an old dilemma of fostering technological development versus granting access to social services, such as healthcare. This paper explores the case of Brazil, a country that has developed large-scale health-inspired industrial policies, but is, yet, little understood. Brazil's experience suggests that progressive healthcare bureaucrats can create innovative practices for technology and knowledge transfers. It also demonstrates that highly competitive pharmaceutical firms can collaborate with each other, if a government provides them the right incentives. Reforming regulatory policies is crucial for guaranteeing high-quality products in developing countries, but governments must play a crucial role in supporting local firms to adapt to these regulations. These findings send a strong message to global health policymakers and practitioners on the conditions to create a suitable environment for local production of medical products.
全球卫生界越来越提倡在发展中国家生产药品,以此促进技术转让、能力建设并改善药品的可及性。然而,在这些国家推进药品制造的努力引发了一个古老的困境,即既要促进技术发展,又要让社会服务(如医疗保健)能够惠及民众。本文探讨了巴西的案例,该国制定了大规模的以卫生为导向的产业政策,但人们对其了解甚少。巴西的经验表明,有进取心的医疗保健官僚可以为技术和知识转让创造创新做法。它还表明,如果政府提供正确的激励措施,竞争激烈的制药公司可以相互合作。改革监管政策对于确保发展中国家的高质量产品至关重要,但政府必须在支持当地公司适应这些法规方面发挥关键作用。这些发现为全球卫生政策制定者和实践者传达了一个强烈的信息,即要为医疗产品的本土化生产创造合适的环境,需要具备哪些条件。